From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy

Experimental Biology and Medicine

Volumn 240, Issue 8, 2015, Pages 1087-1098

  Firor, Amelia E ^a   Jares, Alexander ^a,b   Ma, Yupo ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Cancer; immunology molecular; lymphocyte; medicine oncology; therapy; tumor

Indexed keywords

CANCER TESTIS ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 7; MELAN A; MELANOMA ANTIGEN 3; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN PRESENTING CELL; ARTICLE; BCG VACCINATION; CANCER RECURRENCE; CELL THERAPY; CYTOKINE INDUCED KILLER CELL; DOWN REGULATION; GENE SEQUENCE; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; OSTEOSARCOMA; PROTEIN EXPRESSION; T LYMPHOCYTE; TUBERCULOSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL DESTRUCTION; UPREGULATION; ANIMAL; B LYMPHOCYTE; GENETICS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY;

ANIMALS; ANTIGENS, CD19; B-LYMPHOCYTES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84939529597     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370215584936     Document Type: Article

References (64)

1. R.KorngoldJ.Sprent. Graft-versus-host disease in experimental allogeneic bone marrow transplantation. Proc Soc Exp Biol Med Soc Exp Biol Med1991; 197: 12–8.
2. S.L.MaudeN.FreyP.A.ShawR.AplencD.M.BarrettN.J.BuninA.ChewV.E.GonzalezZ.ZhengS.F.LaceyY.D.MahnkeJ.J.MelenhorstS.R.RheingoldA.ShenD.T.TeacheyB.L.LevineC.H.JuneD.L.PorterS.A.Grupp. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med2014; 371: 1507–17.
3. Stewart BW, Wild C. International Agency for Research on Cancer, World Health Organization. World cancer report 2014. Lyon: WHO Press, 2014. xiv, 630 p
4. L.Gross. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res1943; 3: 326–33.
5. E.J.Foley. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res1953; 13: 835–7.
6. E.F.McCarthy. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthopaed J2006; 26: 154–8.
7. Y.-W.ZangX.-D.GuJ.-B.XiangZ.-Y.Chen. Clinical application of adoptive T cell therapy in solid tumors. Med Sci Monit2014; 20: 953–9.
8. C.L.LarsonR.E.BakerR.N.UshijimaM.B.BakerC.Gillespie. Immunotherapy of Friend disease in mice employing viable BCG vaccine. Proc Soc Exp Biol Med Soc Exp Biol Med1972; 140: 700–2.
9. K.Murphy. Janeway’s immunobiology, 8th ed. New York, NY: Garland Science, 2011.
10. M.SaraivaA.O'Garra. The regulation of IL-10 production by immune cells. Nat Rev Immunol2010; 10: 170–81.
11. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer2012; 12: 252–64.
12. J.Weber. Immune checkpoint proteins: a new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol2010; 37: 430–9.
13. M.E.KeirM.J.ButteG.J.FreemanA.H.Sharpel. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol2008; 26: 677–704.
14. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer2012; 12: 252–64.
15. R.D.Harvey. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther2014; 96: 214–23.
16. C.BlankJ.KuballS.VoelklH.WiendlB.BeckerB.WalterO.MajdicT.F.GajewskiM.TheobaldR.AndreesenA.Mackensen. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer2006; 119: 317–27.
17. R.S.HerbstJ.C.SoriaM.KowanetzG.D.FineO.HamidM.S.GordonJ.A.SosmanD.F.McDermottJ.D.PowderlyS.N.GettingerH.E.KohrtL.HornD.P.LawrenceS.RostM.LeabmanY.XiaoA.MokatrinH.KoeppenP.S.HegdeI.MellmanD.S.ChenF.S.Hodi. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature2014; 515: 563–7.
18. Y.IwaiS.TerawakiT.Honjo. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol2005; 17: 133–44.
19. F.HiranoK.KanekoH.TamuraH.D.DongS.D.WangM.IchikawaC.RietzD.B.FliesJ.S.LauG.F.ZhuK.TamadaL.P.Chen. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res2005; 65: 1089–96.
20. J.R.BrahmerS.S.TykodiL.Q.ChowW.J.HwuS.L.TopalianP.HwuC.G.DrakeL.H.CamachoJ.KauhK.OdunsiH.C.PitotO.HamidS.BhatiaR.MartinsK.EatonS.ChenT.M.SalayS.AlaparthyJ.F.GrossoA.J.KormanS.M.ParkerS.AgrawalS.M.GoldbergD.M.PardollA.GuptaJ.M.Wigginton. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med2012; 366: 2455–65.
21. S.L.TopalianF.S.HodiJ.R.BrahmerS.N.GettingerD.C.SmithD.F.McDermottJ.D.PowderlyR.D.CarvajalJ.A.SosmanM.B.AtkinsP.D.LemingD.R.SpigelS.J.AntoniaL.HornC.G.DrakeD.M.PardollL.ChenW.H.SharfmanR.A.AndersJ.M.TaubeT.L.McMillerH.XuA.J.KormanM.Jure-KunkelS.AgrawalD.McDonaldG.D.KolliaA.GuptaJ.M.WiggintonM.Sznol. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med2012; 366: 2443–54.
22. E.SharonH.StreicherP.GoncalvesH.X.Chen. Immune checkpoints in cancer clinical trials. Chin J Cancer2014; 33: 434–44.
23. C.RobertG.V.LongB.BradyC.DutriauxM.MaioL.MortierJ.C.HasselP.RutkowskiC.McNeilE.Kalinka-WarzochaK.J.SavageM.M.HernbergC.LebbeJ.CharlesC.MihalcioiuV.Chiarion-SileniC.MauchF.CognettiA.AranceH.SchmidtD.SchadendorfH.GogasL.Lundgren-ErikssonC.HorakB.SharkeyI.M.WaxmanV.AtkinsonP.A.Ascierto. Nivolumab in previously untreated melanoma without BRAF mutation. New Engl J Med2015; 372: 320–30.
24. M.R.GreenS.MontiS.J.RodigP.JuszczynskiT.CurrieE.O'DonnellB.ChapuyK.TakeyamaD.NeubergT.R.GolubJ.L.KutokM.A.Shipp. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood2010; 116: 3268–77.
25. S.M.AnsellA.M.LesokhinI.BorrelloA.HalwaniE.C.ScottM.GutierrezS.J.SchusterM.M.MillensonD.CattryG.J.FreemanS.J.RodigB.ChapuyA.H.LigonL.ZhuJ.F.GrossoS.Y.KimJ.M.TimmermanM.A.ShippP.Armand. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med2015; 372: 311–9.
26. S.D.BlackburnA.CrawfordH.ShinA.PolleyG.J.FreemanE.J.Wherry. Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. J Virol2010; 84: 2078–89.
27. S.D.BlackburnH.ShinG.J.FreemanE.J.Wherry. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A2008; 105: 15016–21.
28. A.SnyderV.MakarovT.MerghoubJ.YuanJ.M.ZaretskyA.DesrichardL.A.WalshM.A.PostowP.WongT.S.HoT.J.HollmannC.BruggemanK.KannanY.LiC.ElipenahliC.LiuC.T.HarbisonL.WangA.RibasJ.D.WolchokT.A.Chan. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med2014; 371: 2189–99.
29. D.A.MahviJ.V.MeyersA.J.TatarA.ContrerasM.SureshG.E.LeversonS.SenC.S.Cho. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice. J Immunother2015; 38: 54–61.
30. R.DasR.VermaM.SznolC.S.BoddupalliS.N.GettingerH.KlugerM.CallahanJ.D.WolchokR.HalabanM.V.DhodapkarK.M.Dhodapkar. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol2015; 194: 950–9.
31. J.D.WolchokH.KlugerM.K.CallahanM.A.PostowN.A.RizviA.M.LesokhinN.H.SegalC.E.AriyanR.A.GordonK.ReedM.M.BurkeA.CaldwellS.A.KronenbergB.U.AgunwambaX.ZhangI.LowyH.D.InzunzaW.FeelyC.E.HorakQ.HongA.J.KormanJ.M.WiggintonA.GuptaM.Sznol. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med2013; 369: 122–33.
32. S.A.RosenbergB.S.PackardP.M.AebersoldD.SolomonS.L.TopalianS.T.ToyP.SimonM.T.LotzeJ.C.YangC.A.SeippC.SimpsonC.CarterS.BockD.SchwartzentruberJ.P.WeiD.E.White. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma – a preliminary-report. N Engl J Med1988; 319: 1676–80.
33. S.A.RosenbergM.E.Dudley. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol2009; 21: 233–40.
34. J.J.HongS.A.RosenbergM.E.DudleyJ.C.YangD.E.WhiteJ.A.ButmanR.M.Sherry. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res2010; 16: 4892–8.
35. M.E.DudleyJ.R.WunderlichT.E.SheltonJ.EvenS.A.Rosenberg. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother2003; 26: 332–42.
36. C.JochemsJ.Schlom. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med2011; 236: 567–79.
37. Z.DembicW.HaasS.WeissJ.McCubreyH.KieferH.VonboehmerM.Steinmetz. Transfer of specificity by murine alpha-t-cell and beta-t-cell receptor genes. Nature1986; 320: 232–8.
38. R.A.MorganM.E.DudleyJ.R.WunderlichM.S.HughesJ.C.YangR.M.SherryR.E.RoyalS.L.TopalianU.S.KammulaN.P.RestifoZ.ZhengA.NahviC.R.de VriesL.J.Rogers-FreezerS.A.MavroukakisS.A.Rosenberg. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science2006; 314: 126–9.
39. L.A.JohnsonR.A.MorganM.E.DudleyL.CassardJ.C.YangM.S.HughesU.S.KammulaR.E.RoyalR.M.SherryJ.R.WunderlichC.-C.R.LeeN.P.RestifoS.L.SchwarzA.P.CogdillR.J.BishopH.KimC.C.BrewerS.F.RudyC.VanWaesJ.L.DavisA.MathurR.T.RipleyD.A.NathanC.M.LaurencotS.A.Rosenberg. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood2009; 114: 535–46.
40. M.R.ParkhurstJ.C.YangR.C.LanganM.E.DudleyD.-A.N.NathanS.A.FeldmanJ.L.DavisR.A.MorganM.J.MerinoR.M.SherryM.S.HughesU.S.KammulaG.Q.PhanR.M.LimS.A.WankN.P.RestifoP.F.RobbinsC.M.LaurencotS.A.Rosenberg. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther2011; 19: 620–6.
41. K.W.HanceH.E.ZeytinJ.W.Greiner. Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines. Mutat Res Fundam Mol Mech Mutagen2005; 576: 132–54.
42. K.HauptM.RoggendorfK.Mann. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp Biol Med2002; 227: 227–37.
43. A.J.G.SimpsonO.L.CaballeroA.JungbluthY.T.ChenL.J.Old. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer2005; 5: 615–25.
44. P.F.RobbinsR.A.MorganS.A.FeldmanJ.C.YangR.M.SherryM.E.DudleyJ.R.WunderlichA.V.NahviL.J.HelmanC.L.MackallU.S.KammulaM.S.HughesN.P.RestifoM.RaffeldC.-C.R.LeeC.L.LevyY.F.LiM.El-GamilS.L.SchwarzC.LaurencotS.A.Rosenberg. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol2011; 29: 917–24.
45. M.SangY.LianX.ZhouB.Shan. MAGE-A family: attractive targets for cancer immunotherapy. Vaccine2011; 29: 8496–500.
46. G.P.LinetteE.A.StadtmauerM.V.MausA.P.RapoportB.L.LevineL.EmeryL.LitzkyA.BaggB.M.CarrenoP.J.CiminoG.K.Binder-SchollD.P.SmethurstA.B.GerryN.J.PumphreyA.D.BennettJ.E.BrewerJ.DukesJ.HarperH.K.Tayton-MartinB.K.JakobsenN.J.HassanM.KalosC.H.June. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood2013; 122: 863–71.
47. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, Bennett AD, Pumphrey NJ, Williams DD, Binder-Scholl G, Kulikovskaya I, Levine BL, Riley JL, Varela-Rohena A, Stadtmauer EA, Rapoport AP, Linette GP, June CH, Hassan NJ, Kalos M, Jakobsen BK. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013;5
48. A.Di StasiS.K.TeyG.DottiY.FujitaA.Kennedy-NasserC.MartinezK.StraathofE.LiuA.G.DurettB.GrilleyH.LiuC.R.CruzB.SavoldoA.P.GeeJ.SchindlerR.A.KranceH.E.HeslopD.M.SpencerC.M.RooneyM.K.Brenner. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med2011; 365: 1673–83.
49. J.N.KochenderferW.H.WilsonJ.E.JanikM.E.DudleyM.Stetler-StevensonS.A.FeldmanI.MaricM.RaffeldD.-A.N.NathanB.J.LanierR.A.MorganS.A.Rosenberg. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood2010; 116: 4099–102.
50. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3
51. D.L.PorterB.L.LevineM.KalosA.BaggC.H.June. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med2011; 365: 725–33.
52. S.A.GruppM.KalosD.BarrettR.AplencD.L.PorterS.R.RheingoldD.T.TeacheyA.ChewB.HauckJ.F.WrightM.C.MiloneB.L.LevineC.H.June. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med2013; 368: 1509–18.
53. C.H.J.LamersS.SleijferA.G.VultoW.H.J.KruitM.KliffenR.DebetsJ.W.GratamaG.StoterE.Oosterwijk. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol2006; 24: e20–2.
54. C.LamersP.van ElzakkerS.van SteenbergenJ.OosterwijkS.SleijferR.DebetsJ.Gratama. Immune responses to transgene and retroviral vector in patients treated with ex vivo engineered T-cells. Immunology2012; 137: 688–688.
55. R.A.MorganJ.C.YangM.KitanoM.E.DudleyC.M.LaurencotS.A.Rosenberg. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther2010; 18: 843–51.
56. A.Di StasiS.-K.TeyG.DottiY.FujitaA.Kennedy-NasserC.MartinezK.StraathofE.LiuA.G.DurettB.GrilleyH.LiuC.R.CruzB.SavoldoA.P.GeeJ.SchindlerR.A.KranceH.E.HeslopD.M.SpencerC.M.RooneyM.K.Brenner. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med2011; 365: 1673–83.
57. C.RobertB.KaraszewskaJ.SchachterP.RutkowskiA.MackiewiczD.StroiakovskiM.LichinitserR.DummerF.GrangeL.MortierV.Chiarion-SileniK.DrucisI.KrajsovaA.HauschildP.LoriganP.WolterG.V.LongK.FlahertyP.NathanA.RibasA.M.MartinP.SunW.CristJ.LegosS.D.RubinS.M.LittleD.Schadendorf. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med2015; 372: 30–9.
58. K.BirkholzA.HombachC.KrugS.ReuterM.KershawE.KaempgenG.SchulerH.AbkenN.SchaftJ.Doerrie. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4(+) and CD8(+) T cells for use in the adoptive immunotherapy of cancer. Gene Ther2009; 16: 596–604.
59. G.L.BeattyA.R.HaasM.V.MausD.A.TorigianM.C.SoulenG.PlesaA.ChewY.ZhaoB.L.LevineS.M.AlbeldaM.KalosC.H.June. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res2014; 2: 112–20.
60. R.HassanS.BullockA.PremkumarR.J.KreitmanH.KindlerM.C.WillinghamI.Pastan. Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res2007; 13: 5144–9.
61. S.H.YoonJ.M.LeeH.I.ChoE.K.KimH.S.KimM.Y.ParkT.G.Kim. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther2009; 16: 489–97.
62. M.GerlingerA.J.RowanS.HorswellJ.LarkinD.EndesfelderE.GronroosP.MartinezN.MatthewsA.StewartP.TarpeyI.VarelaB.PhillimoreS.BegumN.Q.McDonaldA.ButlerD.JonesK.RaineC.LatimerC.R.SantosM.NohadaniA.C.EklundB.Spencer-DeneG.ClarkL.PickeringG.StampM.GoreZ.SzallasiJ.DownwardP.A.FutrealC.Swanton. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med2012; 366: 883–92.
63. M.P.McCormackT.H.Rabbitts. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med2004; 350: 913–22.
64. L.BiascoS.ScalaL.Basso RicciF.DionisioC.BaricordiA.CalabriaS.GiannelliN.CieriF.BarzaghiR.PajnoH.Al-MousaA.ScarselliC.CancriniC.BordignonM.G.RoncaroloE.MontiniC.BoniniA.Aiuti. In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. Sci Transl Med2015; 7: 273ra13–273ra13.